Skip to content
Open access

Rapid Antifungal Susceptibility Classification of Aspergillus Species Using AI-Assisted Analysis of Routine MALDI-TOF MS Spectra: A Proof-of-Concept Study.

Sep 2026 · Annals of Laboratory Medicine · 0 citations
Medicine

Abstract

Background The increasing prevalence of antifungal-resistant Aspergillus isolates underscores the need for rapid antifungal susceptibility testing. In this proof-of-concept study, we evaluated whether artificial intelligence (AI) can enable rapid antifungal susceptibility classification of Aspergillus species using routine matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS). Methods Models were developed using MALDI-TOF MS spectra for 240 isolates (Aspergillus flavus N=126, A. fumigatus N=75, Aspergillus lentulus N=39). Their performance in predicting susceptibility to four antifungal agents (voriconazole, posaconazole, itraconazole, and amphotericin B) was evaluated using a validation set comprising A. flavus (N=24), A. fumigatus (N=24), and A. lentulus (N=22), based on categorical agreement (CA), very major error (VME), major error (ME), sensitivity, and specificity. Results Although spectrum-level evaluation showed excellent analytical discrimination, isolate-level clinical evaluation demonstrated limited performance across seven species-antifungal agent combinations. Across these combinations, the AI models achieved a mean CA of 56.0%, with VME and ME rates of 53.3% and 45.2%, respectively. Sensitivity ranged from 0% to 100% and specificity from 18.2% to 87.5%, indicating inconsistent susceptibility classification performance across species-antifungal agent combinations. Conclusions AI-assisted analysis of routine MALDI-TOF MS spectra showed the feasibility of classifying antifungal susceptibility in Aspergillus spp. However, its clinical performance across species-antifungal agent combinations was limited. Further optimization, evaluation with larger multicenter datasets, and external validation are required before considering clinical adoption.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.